Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II tislelizumab + GemOx ± rituximab in relapsed/refractory EBV-positive DLBCL (canceled)
ChiCTR2300076513Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Ningbo University
- Start
- Nov 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in diffuse large B-cell lymphoma (DLBCL), sponsored by First Affiliated Hospital of Ningbo University. Primary endpoint: Overall response rate. Planned start Nov 2023; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2300076513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300076513.